2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1777 Follicular lymphoma survivors have a time-dependent increased risk of second primary malignancies: A large population-based SEER study

Mohammad Abdul-Jaber Othman Abdulla, MD, Bryan Valcarcel, MD, MPH2, Javier Retamales3, Eduardo Edelman Saul, MD4, Kelly Jasmin Meza-Capcha, MD5, Anath Christopher Lionel, MD, PhD6, Chijioke C Nze, MD, MPH7, Luis E. Fayad, MD8, Hun Ju Lee, MD9, Sairah Ahmed, MD10, Maria Alma Rodriguez11, Paolo Strati, MD12, Christopher R. Flowers Jr, MD, MS13, Luis Malpica, MD14
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Louisiana State University Health Sciences Center New Orleans, Lake Charles, Louisiana, United States
4 Novant Health Cancer Institute, Winston-Salem, North Carolina, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Survival after follicular lymphoma (FL) has improved substantially in the rituximab era, making second primary malignancies (SPMs) an increasingly important survivorship concern. Prior studies have often grouped FL with other non-Hodgkin lymphomas, lacked competing-risk methodology, or incompletely characterized the temporal pattern of excess cancer risk among FL survivors.

 

Methods: We identified 55,616 patients whose first or only malignant primary was FL, diagnosed between 2000 and 2022 in the SEER 17 registries database. Patient-level SPMs were defined as malignancies diagnosed more than 2 months after FL diagnosis, excluding subsequent FL and diffuse large B-cell lymphoma (DLBCL). Subsequent DLBCL was analyzed separately as an imperfect registry-based surrogate for possible histologic transformation. Cumulative incidence was estimated using the Aalen-Johansen method, with death treated as a competing event. Standardized incidence ratios (SIRs) compared observed subsequent invasive cancers, excluding non-melanoma skin cancer, with age-, sex-, race-, and calendar year–matched population rates across three latency intervals. Absolute excess risks (AERs) were expressed per 10,000 person-years.

 

Results: Median age was 63 years, and median potential follow-up was 130 months. Overall, 7,174 patients (12.9%) developed at least one qualifying SPM, and 2,253 (4.1%) developed subsequent DLBCL. The 5-, 10-, and 15-year cumulative incidences were 7.4%, 13.0%, and 17.4% for SPM and 2.5%, 4.2%, and 5.4% for subsequent DLBCL, respectively. The most frequent SPMs were lung/bronchus, prostate, breast, melanoma, and colorectal cancers.

 

In the MP-SIR analysis, 9,725 observed versus 6,404 expected cancers yielded an overall SIR of 1.52 (95% CI, 1.49–1.55) and an AER of 76.97 per 10,000 person-years. Excess risk was highest at 2–59 months (SIR 1.64; 95% CI, 1.59–1.69; AER 88.72), remained elevated at 60–119 months (SIR 1.47; 95% CI, 1.42–1.53; AER 71.15), and persisted at ≥120 months (SIR 1.36; 95% CI, 1.31–1.42; AER 59.87). In an aggregate Poisson trend model, the SIR decreased significantly across successive latency intervals (SIR ratio 0.91 per interval; 95% CI, 0.89–0.93; p-trend <0.001).

 

In site-specific analyses, the highest relative excess was observed for acute myeloid leukemia (SIR 5.10; 95% CI, 4.53–5.72; AER 5.38), followed by leukemia overall (SIR 2.32), thyroid cancer (SIR 2.21), lung cancer (SIR 1.35; AER 7.21), kidney cancer (SIR 1.28), and melanoma (SIR 1.21). Breast cancer (SIR 0.85) and prostate cancer (SIR 0.97) were not increased despite being among the most frequent subsequent diagnoses.

 

Conclusions: In this large contemporary FL cohort, survivors had a 52% excess risk of subsequent invasive cancers compared with the general population, corresponding to approximately 60–89 excess cancers per 10,000 person-years across latency intervals. The excess risk declined over time but remained evident beyond 10 years, supporting coordinated long-term survivorship care beyond the first decade after diagnosis and adherence to established cancer-screening recommendations.

Mohammad Abdul-Jaber Othman Abdulla, MD: No relevant conflicts of interest to declare.